ClinicalTrials.gg
CompletedNCT00447993Updated Aug 13, 2024Results posted

A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa

A Phase 2 interventional study of Low Dose NT-501 and High Dose NT-501 in Retinitis Pigmentosa, sponsored by Neurotech Pharmaceuticals. Completed at 11 sites in United States. Open to participants aged 18 Years to 68 Years. Per ClinicalTrials.gov, last updated 2024-08-13.

Sponsored by Neurotech Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years to 68 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 119 studies in Retinitis Pigmentosa with a site in United States — 20 open to participants now, 44 under way, 6 of them phase 3. Retinitis Pigmentosa · United States.

Enrollment
17th of 78
67 · median 21
Started
2007
with 4 others
Phase 2
15 of 119
none open now
Registered
18th of 119
by date
Lead sponsor
3 of 119
Neurotech Pharmaceuticals

Among the 119 studies in Retinitis Pigmentosa with a site in United States, this one is the 17th largest by enrollment of the 78 interventional ones that give a count, is one of 5 that started in 2007, is one of 15 in phase 2, and was the 18th registered.

Retinitis Pigmentosa

278 studies on the registry are indexed under Retinitis Pigmentosa; 72 are open to participants now.

Browse Retinitis Pigmentosa studies →

Open to participants now

20 of the 119 studies in Retinitis Pigmentosa with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Retinitis Pigmentosa studies recruiting now, 37 (76%) set no upper age limit and 7 (14%) stop at 75 or younger; 16 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 68 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 119 studies in Retinitis Pigmentosa with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to look at the safety and effectiveness of CNTF implants on vision in persons with retinitis pigmentosa, Usher type II \& III, and Choroideremia. This research is being done because there are no effective therapies for people with these retinal degenerations. They are genetic disorders that affect our ability to see at night, and later cause tunnel vision and loss of central vision. Retinal degenerations affect the retina, a light sensitive layer of cells in the back of the eye. Slowly over time, these cells die and cause permanent loss of vision.

The implant is a small capsule that contains human retinal pigment epithelium cells. These cells have been given the ability to make CNTF and release it through the capsule membrane into the surrounding fluid. This study will look at the effect of the implant on vision loss by retinitis pigmentosa, Usher type II \& III, and Choroideremia. In this study, two different CNTF dose levels will be used: a high dose and a low dose in one eye, as well as a sham (or placebo) surgery in the other eye.

Read the detailed description

This study will involve about 16 visits over 1½ years for specific tests of the participant's vision and health. These visits may include visual exams, blood draw for laboratory testing, brief medical history and exam, and occasionally a questionnaire (survey), in addition to the visit for the surgical procedures. The primary effectiveness outcome for this study will be a visual acuity score one year after the implant surgery. There will be about 13 centers participating in this study, and up to 60 people enrolled across the US. Each participant joining the study who has completed initial screening will then be scheduled to have a brief surgical procedure performed on each eye, one of which will include a very small cell-filled implant. Follow-up visits for repeat assessments will be required regularly to determine if the implant being tested is safe and effective for use to treat RP.

03

Conditions studied

  • Retinitis Pigmentosa

Keywords

  • Retinitis Pigmentosa
  • eye disease
  • retinal disorder
  • CNTF
04

Who can participate

Ages eligible
18 Years to 68 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant was older than 18, but less than 68 years of age.
  2. Participant understood and signed the . If the participant's vision was impaired to the point where he/she could not read the informed consent document, the document would be read to the participant in its entirety.
  3. Females of (women with last menses \<1 year prior to screening) agreed to use an effective form of from study onset until they completed the 18-month study visit.
  4. Participant was medically able to undergo ophthalmic surgery for the NT-501 device.
  5. Participant's clinical diagnosis was consistent with retinal degeneration in the set of retinitis pigmentosa (RP) dystrophies characterized by the following features:

    1. clinical evidence of progressive photoreceptor cell dysfunction and degeneration of the outer retina.
    2. intraretinal bone-spicule'-like pigment observed in clinical examination (not necessarily applicable to choroideremia).
    3. peripheral visual field constriction documented on standard testing.
    4. symptomatic night blindness.
    5. reduction of both rod and cone electroretinogram (ERG) responses. Individuals diagnosed with Retinitis Pigmentosa, Usher Syndrome Type 2 or Type 3 (without profound deafness or cochlear implant) or with Choroideremia (CHM) and who met the inclusion criteria were considered as potential candidates for this study. A maximum of 5 Usher Syndrome Type 2 or Type 3 and a maximum of 5 Choroideremia participants could be enrolled in this trial.
  6. Each eye had a visual acuity score of at least 24 (20/320) and no more than 63 (20/63) letters.
  7. Each eye had an ERG amplitude reduced below the 95% limit of normal (CI) per site by Full Field 28-32 Hz flicker.

Exclusion criteria

Exclusion Criteria:

  1. Participant was medically unable to comply with study procedures or follow-up visits.
  2. Participant had glaucoma (defined as independent optic atrophy causing vision loss), irrespective of whether it was currently treated or untreated.
  3. Participant had classic syndromic RP.
  4. Participant had optic nerve atrophy beyond modest pallor, primary cone-rod dystrophy, unilateral bulls-eye maculopathy, cystoid maculopathy as judged by OCT reading center, or other retinal dystrophy.
  5. Participant who had any of the following lens opacities: cortical opacity > standard 3, posterior subcapsular opacity > standard 3, or a nuclear opacity > standard 3 as measured on the AREDS clinical lens grading system.
  6. Participant had chronic requirement (e.g., > or =4 weeks at a time) for ocular medications or has disease(s) that in the judgment of the examining physician were vision threatening, toxic to the lens, retina, or optic nerve or might affect the primary outcome.
  7. Participant had a requirement of acyclovir and/or related products during study duration.

    To be eligible for this study, the participant must have discontinued use of these products prior to enrollment and must not continue with the products until after they had completed the study.

  8. Participant had evidence of corneal opacification or lack of optical clarity.
  9. Participant had undergone lens removal in the last 3 months, with or without intra-ocular lens implantation, or had undergone intra-ocular lens replacement within 6 months prior to enrollment.
  10. Participant was receiving systemic or other medications.
  11. Participant had undergone LASIK surgery or other refractive surgery for either eye in less than 6 months prior to screening.
  12. Participant was currently participating in or had participated in any other clinical trial of a drug by ocular or systemic administration within the last 6 months.
  13. Participant had previous exposure to an intra-ocular device or implant into the eye (excluding intra-ocular lens).
  14. Participant had uveitis or other retinal inflammatory disease.
  15. Participant was receiving oral or other insulin treatment for diabetes.
  16. Participant who had a history of myocardial infarction within the last 12 months.
  17. Participant was pregnant or lactating.
  18. Participant was considered immunodeficient or had a known history of . A laboratory test for HIV was performed, and a positive result was also an exclusion criterion.
  19. Participant with a history of ocular herpes zoster.
  20. Participant was on chemotherapy.
  21. Participant had a history of , except study participants having cancer treated successfully ≥5 years prior to inclusion in the trial.
  22. Participant with severe hearing disabilities in both ears.
  23. Participant with diabetic retinopathy in either eye.
  24. Participant had history of retinal detachment in either eye.
  25. Participant had been diagnosed and treated for amblyopia as an infant.
  26. Participant with a history of Pars Plana Vitrectomy.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Low Dose NT-501

    NT-501 Low Dose Implant: encapsulated cell therapy that delivers ciliary neurotrophic factor to the retina Sham Implant in Fellow Eye

    Combination Product: Low Dose NT-501

  • Experimental
    High Dose NT-501

    NT-501 High Dose Implant: encapsulated cell therapy that delivers ciliary neurotrophic factor to the retina Sham Implant in Fellow Eye

    Combination Product: High Dose NT-501

Interventions

  • Combination productLow Dose NT-501

    Low Dose NT-501 Implanted in study eye and fellow eye received sham surgery

    Also known as: CNTF implant

  • Combination productHigh Dose NT-501

    High Dose NT-501 Implanted in study eye and fellow eye received sham surgery

    Also known as: CNTF implant

06

What researchers measure

Primary outcomes

  1. The Primary Outcome is the Change in Best-corrected Visual Acuity (BCVA) Using the Electronic Visual Acuity (EVA) Technology at Month 12.

    The primary efficacy endpoint was the proportion of patients demonstrating an improvement in best-corrected visual acuity (BCVA), defined as an increase of 10 letters or more at the 1-Year post-implant visit (pre-explant, if explant is completed). No response is defined as an improvement of \<10 letters.

    Time frame: 12 months post-implant

Secondary outcomes

  1. Number of Participants With and Without Best Corrected Visual Acuity Response Over the 18-month Follow-up Period (Months 1, 3, 6, 12 and 18)

    The key visits for efficacy assessments were Months 1, 3, 6, 12 and 18. At these time points, BCVA was measured 3 times and the mean outcome reported. The assessments were conducted by masked technicians. The change from baseline for BCVA was summarized by time. Response is defined as an improvement in visual acuity by an increase of 10 letters or more whereas no response is \<10 letters.

    Time frame: From initial implant to 18 months post-implant

07

Results

Posted Aug 13, 2024

Participant flow

The total number of participant in the low dose group was 22 and the high dose group was 45 since each patient consented to treatment in one eye and sham treatment in the other eye.

Participant flow — Overall Study
MilestoneLow Dose Arm - ImplantLow Dose Arm - ShamHigh Dose Arm - ImplantHigh Dose Arm - Sham
Started22224545
Completed22224141
Not completed0044
Withdrew: Lost to follow-up0022
Withdrew: Withdrawal by subject0022

Outcome measures

PrimaryThe Primary Outcome is the Change in Best-corrected Visual Acuity (BCVA) Using the Electronic Visual Acuity (EVA) Technology at Month 12.

The primary efficacy endpoint was the proportion of patients demonstrating an improvement in best-corrected visual acuity (BCVA), defined as an increase of 10 letters or more at the 1-Year post-implant visit (pre-explant, if explant is completed). No response is defined as an improvement of \<10 letters.

Time frame:
12 months post-implant
Reported as:
Number · participants
The Primary Outcome is the Change in Best-corrected Visual Acuity (BCVA) Using the Electronic Visual Acuity (EVA) Technology at Month 12.
participantsLow Dose Arm - ImplantLow Dose Arm - ShamHigh DoseHigh Dose Arm - Sham
Response (Greater than or equal to 10 letter improvement)1131
No Response20203941
SecondaryNumber of Participants With and Without Best Corrected Visual Acuity Response Over the 18-month Follow-up Period (Months 1, 3, 6, 12 and 18)

The key visits for efficacy assessments were Months 1, 3, 6, 12 and 18. At these time points, BCVA was measured 3 times and the mean outcome reported. The assessments were conducted by masked technicians. The change from baseline for BCVA was summarized by time. Response is defined as an improvement in visual acuity by an increase of 10 letters or more whereas no response is \<10 letters.

Time frame:
From initial implant to 18 months post-implant
Reported as:
Count of participants · Participants
Number of Participants With and Without Best Corrected Visual Acuity Response Over the 18-month Follow-up Period (Months 1, 3, 6, 12 and 18)
ParticipantsLow Dose Arm - ImplantLow Dose Arm - ShamHigh DoseHigh Dose Arm - Sham
1 month post-implant: Response1131
1 month post-implant: No Response21214042
3 months post-implant: Response2120
3 months post-implant: No Response20214042
6 months post-implant: Response1042
6 months post-implant: No Response20213840
12 months post-implant: Response1131
12 months post-implant: No Response20203941
18 months post-implant: Response0220
18 months post-implant: No Response19173032

Adverse events

Collected over Adverse Events were collected from time of the consent through 18 months post-implant.. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Dose0/22 (0%)1/22 (4.5%)22/22 (100%)
High Dose0/43 (0%)0/22 (0%)42/43 (97.7%)
Most frequent serious events
Most frequent serious events
EventLow DoseHigh Dose
Pelvic FractureInjury, poisoning and procedural complications1/220/22
Upper limb fractureInjury, poisoning and procedural complications1/220/22
Most frequent other events
Showing 10 of 33
Most frequent other events
EventLow DoseHigh Dose
Conjunctival HaemorrhageEye disorders16/2232/43
Conjunctival HyperaemiaEye disorders11/2215/43
Suture related complicationInjury, poisoning and procedural complications10/2211/43
Anterior chamber cellEye disorders7/2212/43
Procedural painInjury, poisoning and procedural complications7/225/43
NasopharyngitisInfections and infestations6/222/43
MiosisEye disorders1/2211/43
Anterior chamber flareEye disorders5/2210/43
Foreign body sensation in eyesEye disorders2/2210/43
Eye painEye disorders2/227/43

Baseline characteristics

Total number of participants in the trial was 67, with 22 participants in the Low Dose Arm and 45 participants in the High Dose Arm. Note, the participants also received a sham surgery in fellow eye on both study arms, which was used as reference therapy. No capsule was implanted in fellow eye. Baseline reports include sham as a separate column for each arm.

Age, Continuous
Age, Continuous(Years)Low Dose Arm - ImplantLow Dose Arm - ShamHigh DoseHigh Dose Arm - ShamTotal
Mean41.1 ± 10.541.1 ± 10.542.0 ± 11.042.0 ± 11.041.7 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Low Dose Arm - ImplantLow Dose Arm - ShamHigh DoseHigh Dose Arm - ShamTotal
Female88252566
Male1414202068
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Low Dose Arm - ImplantLow Dose Arm - ShamHigh DoseHigh Dose Arm - ShamTotal
Hispanic or Latino332210
Not Hispanic or Latino19194343124
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Low Dose Arm - ImplantLow Dose Arm - ShamHigh DoseHigh Dose Arm - ShamTotal
American Indian or Alaska Native11002
Asian22228
Native Hawaiian or Other Pacific Islander00000
Black or African American114410
White18183939114
More than one race00000
Unknown or Not Reported00000
Ocular History - Years Since RP Diagnosis
Ocular History - Years Since RP Diagnosis(Years)Low Dose Arm - ImplantLow Dose Arm - ShamHigh DoseHigh Dose Arm - ShamTotal
Mean24.66 ± 9.5524.66 ± 9.5521.50 ± 13.2121.50 ± 13.2122.52 ± 12.17
Type of Ocular History
Type of Ocular History(Eyes)Low Dose Arm - ImplantLow Dose Arm - ShamHigh DoseHigh Dose Arm - ShamTotal
Ocular Disease22224545134
Ocular Surgery119212162
Ocular Treatment22228
BCVA Letter Score
BCVA Letter Score(Letters)Low Dose Arm - ImplantLow Dose Arm - ShamHigh DoseHigh Dose Arm - ShamTotal
Mean45.5 ± 11.244.8 ± 10.445.0 ± 10.446.7 ± 9.145.5 ± 10.3
08

Study locations

11 sites
  • Retina-Vitreous Associates Medical Group
    Beverly Hills, California 90211, United States
  • University of Califoria, Davis
    Sacramento, California 95817, United States
  • University of California, San Francisco
    San Francisco, California 94143-0730, United States
  • Retina Group of Florida
    Hollywood, Florida 33021-6746, United States
  • University of Florida
    Jacksonville, Florida 32216-1480, United States
  • Kellogg Eye Center
    Ann Arbor, Michigan 48105, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455-0501, United States
  • NY University Medical Center
    New York, New York 10016, United States
  • Casey Eye Institue
    Portland, Oregon 97239-4197, United States
  • The Hamilton Eye Institute
    Memphis, Tennessee 38163, United States
  • Retina Foundation of Southwest
    Dallas, Texas 75231, United States
09

References and documents

Publications

  • Birch DG, Weleber RG, Duncan JL, Jaffe GJ, Tao W; Ciliary Neurotrophic Factor Retinitis Pigmentosa Study Groups. Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa. Am J Ophthalmol. 2013 Aug;156(2):283-292.e1. doi: 10.1016/j.ajo.2013.03.021. Epub 2013 May 10. PubMed 23668681 ↗
  • Kauper K, McGovern C, Sherman S, Heatherton P, Rapoza R, Stabila P, Dean B, Lee A, Borges S, Bouchard B, Tao W. Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Invest Ophthalmol Vis Sci. 2012 Nov 1;53(12):7484-91. doi: 10.1167/iovs.12-9970. PubMed 23049090 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2007 to primary completion in May 2009, 28 months.

Results were first posted in Aug 2024, 15 years 2 months after primary completion. A results delay was requested in Nov 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2007
First posted
Mar 15, 2007
StartActual
Jan 8, 2007
Primary completionActual
May 26, 2009
CompletionActual
May 26, 2009
Results delay requested
Nov 15, 2016
Results first posted
Aug 13, 2024
Last update
Aug 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00447993
Lead sponsor
Neurotech Pharmaceuticals
Responsible party
Sponsor
First posted
Mar 15, 2007
Start date
Jan 8, 2007
Primary completion
May 26, 2009
Completion
May 26, 2009
Results posted
Aug 13, 2024
Last update
Aug 13, 2024

Study contacts

David Birch, MD
principal investigator · Retina Foundation of the Southwest

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciliary Neurotrophic Factor

Start the discussion